China Isotope & Radiation Corporation and Bayer agree to introduce Xofigo into China

On September 1, China Isotope & Radiation Corporation (CIRC) signed an exclusive distribution agreement with Bayer.

On September 1, China Isotope & Radiation Corporation (CIRC) signed an exclusive distribution agreement with Bayer.

According to the agreement, Bayer will grant CIRC the exclusive right to sell Xofigo® (radium chloride [223Ra] injection) in China.

Xofigo is indicated for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastatic disease.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/09/02/china-isotope-radiation-corporation-and-bayer-agree-to-introduce-xofigo-into-china/.

Leave a Reply

Please Login to Comment